Vimarsana
Biggest News Aggregation in the World

Page 2 - Clin Pract News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clin Pract. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clin Pract Today - Breaking & Trending Today

XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide - Vimarsana News

XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) announced today that XTANDI®...

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Nonmetastatic Prostate Cancer - Vimarsana News

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Nonmetastatic Prostate Cancer

Pfizer and Astellas announce positive top-line results from Phase 3 EMBARK trial MARKHAM, ON, March 23, 2023 /CNW/ - Astellas Pharma Inc. , the parent company of Astellas Pharma Canada, Inc., has... | March 23, 2023

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer - Vimarsana News

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

/PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive...

Iron deficiency in childhood and adolescents - Vimarsana News

Iron deficiency in childhood and adolescents

Iron deficiency in children and adolescents can happen due to the rapid increase in blood volume and muscle mass during growth and development.

Dicer and bevacizumab inhibition hepatocellular carcinoma - Vimarsana News

Dicer and bevacizumab inhibition hepatocellular carcinoma

In this study, we aimed to determine the relationship between Dicer and VEGF in HCC.